Posted by Michael Wonder on 26 Oct 2016
First and only medication approved in Canada for the treatment of binge eating disorder
25 October 2016 - Vyvanse (lisdexamphetamine dimesylate) now indicated for the treatment of moderate to severe binge eating disorder in adults.
Shire Pharma Canada today announces the Health Canada approval of Vyvanse for the treatment of moderate to severe binge eating disorder in adults. Binge eating disorder is the most common eating disorder in adults.
In addition to being more common than anorexia and bulimia combined, binge eating disorder is the most prevalent eating disorder among adult men.
Vyvanse is the first medication with an approved indication for the treatment of binge eating disorder in Canada.
